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Malaria continues to impose a significant disease burden on low- and middle-income countries in the tropics.
However, revolutionary progress over the last 3 years in nucleic acid sequencing, reverse genetics, and
post-genome analyses has generated step changes in our understanding of malaria parasite (Plasmodium spp.)
biology and its interactions with its host and vector. Driven by the availability of vast amounts of genome
sequence data from Plasmodium species strains, relevant human populations of different ethnicities, and
mosquito vectors, researchers can consider any biological component of the malarial process in isolation or in the
interactive setting that is infection. In particular, considerable progress has been made in the area of population
genomics, with Plasmodium falciparum serving as a highly relevant model. Such studies have demonstrated that
genome evolution under strong selective pressure can be detected. These data, combined with reverse genetics,
have enabled the identification of the region of the P. falciparum genome that is under selective pressure and the
confirmation of the functionality of the mutations in the kelch13 gene that accompany resistance to the major
frontline antimalarial, artemisinin. Furthermore, the central role of epigenetic regulation of gene expression and
antigenic variation and developmental fate in P. falciparum is becoming ever clearer. This review summarizes
recent exciting discoveries that genome technologies have enabled in malaria research and highlights some of
their applications to healthcare. The knowledge gained will help to develop surveillance approaches for the
emergence or spread of drug resistance and to identify new targets for the development of antimalarial drugs
and perhaps vaccines.Background
Malaria, caused by unicellular protozoan Plasmodium
spp. parasites, is an ancient disease and remains a
major threat to human health and wellbeing. Five
species of Plasmodium are currently recognized as
causing human malaria, of which the most lethal is
P. falciparum (Pf ). In 2015, the World Health
Organization estimated that the maximal annual bur-
den imposed by malaria, whilst decreasing, still stands
at 214 million (range 149–303 million) cases that
result in 438,000 (range 236,000–623,000) deaths [1].
Drug resistance to frontline antimalarials continues to
arise and spread, exacerbated by slow progress in the
introduction of alternatives. Properly efficacious vac-
cines remain a hope, not a likelihood. Against this
background, genome-based research on malaria seeks* Correspondence: AndyWaters@Glasgow.ac.uk
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as the identification of new drug targets and vaccine
candidates.
The landmark of the completion of the genome
sequence of a laboratory strain of Pf was achieved over
a decade ago [2] (Fig. 1). This has since been accom-
panied, thanks to plummeting costs and advances in
next-generation sequencing (NGS) technologies, by the
whole-genome sequencing (WGS) of a wide range of
species representing all the major clades of the genus,
although the genomes of all known human infectious
Plasmodium species remain to be sequenced [3]. How-
ever, the combination of NGS and WGS has enabled
the development of innovative large-scale genomic
studies, for example, for genomic epidemiology [4].
Such population genomics, fueled by collaborative
consortia (for example, the Malaria Genomic Epidemi-
ology Network (MalariaGEN; http://www.malariagen.net),
have allowed the dynamics of global and local populationle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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genomes to be monitored in response to threats, such
as artemisinin (ART). This is especially true for single-
nucleotide polymorphisms (SNPs), and while other
aspects of genome variation (such as indels and copy
number variation) might currently lag behind, the
gaps in the database are known and are firmly in the
sights of researchers.
The template Plasmodium genomes have provided the
substrate for the application of an explosion of other
post-genome survey technologies that have been largely
exclusively applied to Pf, such as transcriptomics, prote-
omics, metabolomics, and lipidomics, and that map the
general and stage-specific characteristics of malaria para-
sites. These data are warehoused in expensive but critical
community web sites such as PlasmoDB (http://www.Plas
modb.org). This in turn has been exploited by ever
improving forward and reverse genetic capabilities to
assign function to genes, steadily reducing the >60 % of
genes of unknown function that were originally catalogued
[2]. Advances that will be highlighted in this review
include: the unraveling of the molecular mechanisms of
parasite resistance to ART; the functional identifica-
tion of some of the histone-modifying enzymes that
write the epigenetic code (such as Pf histone deacety-
lase 2 (PfHDA2)) and the proteins that read it (such
as Pf heterochromatin protein 1 (PfHP1)) that, with
others (such as RNaseII), play a significant role in the
regulation of antigenic variation and commitment to
sexual development.
Furthermore, the genomes of the host and of a grow-
ing number of mosquito vectors have been characterized
in both increasing number and depth, permitting meta-
analyses of these genomes in combination with Plasmo-
dium infection. These studies have revealed important
loci associated with resistance to the malaria parasite in
the host and vector, respectively [5, 6], and indicate the
genomic hotspots in the genetic arms race that malaria
has stimulated.
We also review the recent advances in this very active
area of malaria genomics and control of gene expression
and emphasize any benefits that these advances may
have for the development of therapies and interventions
(Table 1).
Human genomics
The infrastructure required to effectively collect, collate,
and analyze large genomes for epidemiological studies
(that is, genome-wide association studies (GWAS)) is so
costly that it is best achieved in consortia. These can
work at such a scale that analyses are powered to a de-
gree that GWAS findings become more certain and the
global context of the effect of, for example, human genet-
ics on susceptibility to malaria is more reliably resolved.The African Genome Variation Project recognizes the
significant diversity of ethnicities and, therefore, geno-
types and, through WGS, imputation, and SNP
mapping, seeks to build a database through which
disease incidence and outcome can be reliably associ-
ated with haplotypes [7]. Already, such wider analyses
have confirmed SNP associations with five well-known traits,
including hemoglobinopathies and glucose-6-phosphate
dehydrogenase (G6PD) deficiency, but have refuted 22
others that had been linked by smaller-scale studies [8]. This
study also showed opposing effects of G6PD on different
fatal consequences of malaria infection, revealing a hitherto
unsuspected complexity of associations. Ongoing analyses
have revealed new, although unsurprising, examples
of haplotypes of loci associated with protection from
severe malaria, such as the glycophorin locus on human
chromosome 4 [8, 9].
Vector genomics
In Africa, malaria is mainly transmitted by female
Anopheles gambiae (Ag) mosquitoes. Approaches to
understanding the role of Ag mosquito genomics in
malaria transmission have been similar to those of the
African Genome Variation Project. Thus, the Ag1000G
project (https://www.malariagen.net/projects/ag1000g)
involves 35 working groups that have sampled Ag mosqui-
tos from 13 malaria endemic countries and that aim to
establish the levels of Ag genome diversity, establish popu-
lation structures, and link these to the ecology of disease
transmission. The Anopheles vector genome is very
dynamic. Comparative vector genomics has revealed rapid
gene gain and loss compared with Drosophila and signifi-
cant intragenus diversity and mixing in genes involved
in both insecticide resistance and antimalarial immun-
ity [10, 11]. The nature and extent of such diversity
precludes the application of classic GWAS approaches
and a novel approach of phenotype-driven, pooled se-
quencing coupled with linkage mapping in carefully
selected founder colonies has been used to map vec-
tor phenotypes. This study recently revealed TOLL11
as a gene that protects African mosquitoes against Pf
infection [6].
Parasite genomics
Full genome sequences are now available for many
strains of Pf [2], Plasmodium vivax [12], and Plasmo-
dium knowlesi [13] among the human infectious
parasites. Primate and rodent infectious species that are
frequently used as model parasites have also been
sequenced and include Plasmodium berghei (Pb), Plas-
modium cynomolgi, Plasmodium chabaudi and Plasmo-
dium yoelii [14]. Recently, the genomes of seven further
primate infectious species have become available,
demonstrating the close relationship between Pf and
Fig. 1 Major advances in omics-related fields. This figure highlights landmark studies providing key insights into parasite makeup, development,
and pathogenesis (yellow boxes) as well as crucial technical advances (blue boxes) since the first Plasmodium genomes were published in 2002
[2, 5, 12, 13, 27, 29, 31, 39, 40, 42, 43, 48–50, 53, 54, 57, 66, 114, 115, 151, 153–178]. AID auxin-inducible degron, ART artemisinin, cKD conditional
knockdown, CRISPR clustered regularly interspaced short palindromic repeats, DD destabilization domain, K13 kelch13, Pb P. berghei, Pf P. falciparum,
TSS transcription start site, TF transcription factor, ZNF zinc finger nuclease
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Plasmodium genome consists of 14 linear chromo-
somes of aggregate size of approximately 22 mega-
bases encoding >5000 protein-coding genes. The core,
conserved genome of about 4800 such genes occupies
the central chromosomal regions whilst the multi-
gene families (at least some of which are associated
with antigenic variation) are largely distributed to the
subtelomeric regions. Non-coding RNA (ncRNA)genes [16] and antisense transcription [17, 18] are
being catalogued in Pf but this catalogue probably
remains incomplete as only blood-stage parasites
have been seriously investigated in this regard and
ncRNAs remain largely of unknown significance.
One key feature of Pf is its evolution in the face of
human-imposed selection pressures in the form of drugs
and potentially vaccines. Such pressure has consistently
resulted in the emergence of drug-resistant parasites.
Table 1 Key advances from recent omics studies
Research area Key findings Reference(s)
Genome sequencing WGS and refinement of genome sequences of primate and rodent infectious Plasmodium
species
[13, 154–157, 179]
Genome sequence of cryptic chimpanzee Plasmodium species [158]
Gene expression regulation Discovery of AP2-G as master regulator of gametocytogenesis in Pf and Pb [49, 50]
AP2-G2 functions as a transcription regulator driving gametocyte development [51]
Functional analysis of Pf lifecycle dynamics using transcriptional profiling [180]
Genome-wide TSS mapping in Pf [42]
Acetylome analysis reveals post-translational PTM of ApiAP2 transcription factors [55]
Genome-wide analysis of AP2-O target genes [48]
Post-transcriptional/translational
control
Genome-wide analysis reveals features of the Pf translatome [59, 66]
Analysis of the Pb maternal repressome [64]
Epigenetic control SETvs functions as a regulator of var gene silencing in Pf [98]
Involvement of HP1 in clonal variant gene expression and sexual development [29]
HDA2 mediates var gene silencing and sexual commitment in Pf [27]
BDP1 regulates expression of invasion-related genes [31]
Profiling of histone PTMs in Pf [22]
Gene silencing/editing First description of the use of ZFN and CRISPR-Cas9 genome editing in Plasmodium [115, 116, 140]
Functional adaptation of an AID-based conditional knockdown system in Pb [159]
Antibiotic resistance Analysis of KELCH13-propellermutations in Plasmodium field isolates confirms relation to arte-
misinin resistance
[115, 116]
Identification of UPR pathway involvement in Plasmodium artemisinin resistance [123, 126]
Genome structure First profiling of genome-wide chromosome interactions [39]
Strong correlation between spatial genome structure and gene expression [37]
ncRNAs PfRNaseII exonuclease is involved in group A var gene silencing [84]
Genome-wide search revealed over 1000 novel ncRNAs in Pf [181]
Strand-specific RNA sequencing reveals widespread transcription of antisense RNAs in Pf [16–18]
Antisense lncRNAs regulate expression of cognate var genes in Pf [87]
Virulence/transmission Vector transmission of P. chabaudi chabaudi impacts on parasite virulence [182]
Transcriptome changes during early phase of mosquito infection [183]
Development Global phosphoproteome analysis identified PKG as major intracellular Ca2+ level regulator [184]
PKG regulates Plasmodium egress and evasion [185]
Systematic subtractive bioinformatic analysis identified sex-specific stage V gametocyte pro-
tein marker
[186]
Protein phosphatases are key regulators of Plasmodium development [187]
Population genomics Identification of a novel malaria resistance locus through GWAS in African children [5]
Genomic epidemiology study revels global KELCH13 mutation distribution [160]
Metablomics Lipid metabolism analysis in Pf [151]
AID auxin-inducible degron, CRISPR clustered regularly interspaced short palindromic repeats, GWAS genome-wide association study, lncRNA long non-coding RNA,
ncRNA non-coding RNA, Pb P. berghei, Pf P. falciparum, PTM post-translational modification, SNP single-nucleotide polymorphism, TSS transcription start site, UPR
unfolded protein response, WGS whole-genome sequencing, ZFN zinc finger nuclease
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variation upon which selection may act. In an initial
analysis of 227 parasite samples collected at six different
locations in Africa, Asia, and Oceania, MalariaGEN, the
Oxford-based genomic epidemiology network, identified
more than 86,000 exonic SNPs. This initial SNPcatalogue is described in detail by Manske and col-
leagues [19]. Currently (27 July 2016), the MalariaGEN
database states that for the Pf Community Project, it
has data on 3488 samples from 43 separate locations
in 23 countries and the number of high-quality, fil-
tered exonic SNPs has increased to more than
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be selected for fitter and perhaps more deadly parasites.
Modern NGS and WGS have enabled comparative and
population genomics approaches that have been used to
reveal important features of emerging parasite popula-
tions, for example, in response to drugs.
Parasite development and pathogenesis
Within their mammalian host and mosquito vector
Plasmodium parasites complete a remarkable lifecycle,
alternating between asexual and sexual replication
(Fig. 2). Throughout the Plasmodium lifecycle, regula-
tion of gene expression is orchestrated by a variety of
mechanisms, including epigenetic, transcriptional, post-
transcriptional, and translational control of gene expres-
sion. Owing to the absence of most canonical eukaryotic
transcription factors in the Plasmodium genome [2],
epigenetic control has long been recognized to play an
important role in gene expression regulation.
Epigenetics lies at the very heart of gene expression,
regulating access of the transcriptional machinery to
chromatin [20] via (1) post-translational modifications
(PTMs) of histones, (2) nucleosome occupancy, and (3)
global chromatin architecture. In the past decade,
various histone PTMs have been identified throughout
the Plasmodium lifecycle (reviewed in [21]) and the
existing catalog of modifications in Pf was recently
extended to 232 distinct PTMs, 88 unique to Plasmo-
dium [22]. The majority of detected PTMs show
dynamic changes across the intra-erythrocytic develop-
ment cycle (IDC), likely mirroring changes within chro-
matin organization linked to its transcriptional status.
Methylation and acetylation of N-terminal histone tails
are by far the most studied regulatory PTMs, linked
either to a transcriptionally active chromatin structure
(that is, euchromatin) or to transcriptionally inert het-
erochromatin. In Pf, various genes encoding putative
epigenetic modulators (that is, proteins catalyzing either
the addition or removal of histone PTM marks) have
been identified [23], but only a few have been subjected
to more detailed investigation [24, 25]. Many of the
histone modifiers are essential for Plasmodium develop-
ment, making them a promising target for antimalarial
drugs [26]. In Pf, conditional knockdown of HDA2, a
histone lysine deacetylase (HDAC) catalyzing the re-
moval of acetyl groups from acetylated histone 3 ly-
sine 9 (H3K9ac), resulted in elevated H3K9ac levels
in previously defined heterochromatin regions [27].
H3K9ac is an epigenetic mark associated with tran-
scriptionally active euchromatin [28] and HDA2 de-
pletion resulted in the transcriptional activation of
genes located in heterochromatin regions, leading to
impaired asexual growth and an increased gametocyte
conversion [27]. Interestingly, genes found to bedysregulated by HDA2 knockdown are also known
to be associated with HP1, a key epigenetic player
binding to tri-methylated H3K9 (H3K9me3), linked to
transcriptionally repressed chromatin. Strikingly,
conditional knockdown of PfHP1 recapitulated, to a
much greater extent, the phenotype observed in
HDA2-knockdown mutants [29]. HP1 is believed to
act as a recruitment platform for histone lysine meth-
yltransferases (HKMTs), required for maintenance and
spreading of H3K9me3 marks [30], which is consist-
ent with the reduction of H3K9me3 observed in HP1
knockdown cells [29]. In addition, bromodomain pro-
tein 1 (BDP1) was found to bind to H3K9ac and
H3K14ac marks within transcription start sites (TSSs)
in Pf, among them predominantly invasion-related
genes (Fig. 3a), and BDP1-knockdown parasites con-
sistently failed to invade new erythrocytes. BDP1 also
appears to act as a recruitment platform for other
effector proteins such as BDP2 and members of the
apicomplexan AP2 (ApiAP2) transcription factor
family [31].
In addition to histone PTMs, nucleosome organization
plays a critical role in gene expression regulation in
Plasmodium. In general, heterochromatin is substantially
enriched in nucleosomes compared with euchromatin
[32] and active promoters and intergenic regions in Pf
show markedly reduced nucleosome occupancy [33]. In
addition, common transcript features such as TSSs,
transcription termination sites, and splice donor/
acceptor sites show clearly distinguishable nucleosome
positioning in Pf [34], but previously described dy-
namic changes in nucleosome positioning [32] ap-
peared to be mostly restricted to TSSs during the
IDC [34]. Uniquely in Plasmodium spp., canonical
histones in intergenic regions are replaced by histone
variant H2A.Z [28], which, in concert with the
apicomplexan-specific H2B.Z, establishes a H2A.Z/H2B.Z
double-variant nucleosome subtype enriched at AT-rich
promoter regions and correlates with open chromatin and
active gene transcription [35].
Within the confined space of the nucleus, chromo-
somes are tightly packed into a three-dimensional
structure. This three-dimensional architecture allows
interaction between otherwise distant chromatin regions
possessing regulatory function and facilitates contacts
with other nuclear sub-compartments such as the
nucleolus and the nuclear envelope [36]. Until recently,
knowledge of the chromosome architecture and chroma-
tin interactions in Plasmodium was mostly restricted to
single genomic loci based on fluorescence in situ
hybridization experiments [37]. However, recent advances
in deep-sequencing technologies [38] have for the first
time enabled the genome-wide profiling of chromosome
interactions at kilobase resolution in Plasmodium [37, 39].
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Fig. 2 Plasmodium life cycle. After a mosquito bite, malaria parasites are deposited into the host’s skin and within minutes are carried via the
bloodstream into the liver, where through asexual proliferation within the hepatocytes tens of thousands of merozoites are produced. Following
hepatocyte rupture, merozoites are released into the bloodstream where they can invade the host’s red blood cells (RBC), leading to the initiation
of the intra-erythrocytic development cycle (IDC). During the IDC (lasting about 48–72 h in human and about 24 h in rodent malaria parasites),
Plasmodium parasites multiply asexually through the completion of several morphologically distinct stages within the RBCs. After RBC invasion,
malaria parasites develop via the ring and trophozoite stage into schizonts, each containing a species-specific number of merozoites (typically
10–30). Upon schizont rupture, merozoites are released into the bloodstream, where they can invade new RBCs and initiate a new IDC. However,
a small fraction of ring-stage parasites sporadically differentiate into male or female gametocytes, which are responsible for initiating transmission
back to the mosquito. Through another mosquito blood meal gametocytes are taken up into the mosquito midgut where they are activated and
form male (eight per gametocyte) and female (one) gametes. Following fertilization, the zygote undergoes meiosis (and therefore true sexual
recombination) and develops into a motile, tetraploid ookinete that traverses the midgut and forms an oocyst. Via another round of asexual
proliferation inside the oocyst several thousands of new haploid sporozoites are generated that, upon their release, colonize the mosquito salivary
glands, poised to initiate a new infection of another mammalian host
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appears to lack clearly defined chromosome territories
and chromatin interactions are mainly restricted to intra-
chromosomal contacts showing a clear distance-related
dependency [37, 39]. Inter-chromosomal interactions are
mostly absent in Pf and restricted to centromeres,
telomeres, ribosomal DNA (rDNA) loci, and internal as
well as subtelomeric-localized var genes (further discussed
in the next section). This observed clustering appears to
coincide with transcriptional activity of each cluster.
Interestingly, using three-dimensional chromatin model-
ing, the highly transcribed rDNA genes were proposed to
be localized to the nuclear periphery, which was
previously mainly associated with transcriptionally si-
lenced heterochromatin [40], indicative of perinuclear
transcriptionally active compartments [37].Transcription itself is initiated through binding of the
transcriptional machinery to promoter regions in the
nucleus, resulting in the synthesis of pre-mRNA mole-
cules, which, following extensive processing and nuclear
export, leads to the accumulation of mature mRNAs in
the parasite cytosol [41]. A recent study found evidence
for stage-specific transcription initiation from distinct
TSSs of otherwise identical transcriptional units, giving
rise to developmentally regulated mRNA isoforms [42].
While most canonical eukaryotic transcription factors
are absent from the Plasmodium genome [2], the
ApiAP2 family of DNA-binding proteins comprises by
far the largest group of transcription factors in malaria
parasites [43]. A collection of ApiAP2 proteins is
expressed throughout all stages of the IDC [44], while
other ApiAP2 proteins are expressed outside the IDC
Fig. 3 Malaria parasite genomic components involved in pathogenesis. a The expression of invasion-related genes is regulated through epigenetic and
post-transcriptional mechanisms. Bromodomain protein 2 (BDP2) binds to H3K9ac marks within the promoter region of genes associated with red blood
cell (RBC) invasion (as well as other gene families not depicted here [31]), enabling their transcription. This is likely achieved through the recruitment of
BDP1 and transcription factors (TFs) of the ApiAP2 family. Following transcription during the trophozoite stage, mRNAs encoding invasion-related
proteins are bound by ALBA1 functioning as translation repressor. After progression to the schizont stage, ALBA1 is released, allowing the
timely synthesis of proteins required for merozoite invasion of RBCs. b Experimental findings either directly from studies on ap2-g or from
epigenetically regulated var genes are suggestive of an epigenetically controlled mechanism regulating ap2-g transcription. In sexually committed
parasites, ap2-g is characterized by H3K4me2/3 and H3K9ac histone marks and most likely contains histone variants H2A.Z and H2B.Z located in its
promoter region. BDPs are believed to bind to H3K9ac, facilitating ap2-g transcription. ApiAP2-G drives expression of genes required for
sexual development through binding to a 6/8-mer upstream DNA motif. ap2-g expression itself is believed to be multiplied through an
autoregulatory feedback loop where ApiAP2-G binds to its own promoter that also contains ApiAP2-G motifs. In asexual blood-stage parasites, ap2-g
is transcriptionally silenced by heterochromatin protein 1 (HP1) binding to H3K9me3 histone marks (located in repressive loci in the nuclear periphery).
Histone deacetylase 2 (HDA2) catalyzes the removal of H3K9ac from active ap2-g, facilitating ap2-g silencing. c Monoallelic expression of one of the
approximately 60 members of the erythrocyte membrane protein 1 (EMP1)-encoding var genes is regulated through epigenetic silencing of all but
one var gene copy. The active var is marked by euchromatin post-translational modifications H3K4me2/3 and H3K9ac and histone variants H2A.Z/
H2B.Z located in its promoter region, as well as H3K36me3 covering the whole var gene body but absent from the promoter region. Transcription of
noncoding RNAs associated with the active var gene is facilitated by upstream as well as intronic promoters. All other silenced var genes cluster into
perinuclear repressive loci and are characterized by HP1 binding to H3K9me3 marks. var gene silencing also involves SET2/vs-dependent placing of
H3K36me3 histone marks in promoter regions and is marked by the absence of non-coding RNAs, likely safeguarded through RNaseII exonuclease
activity. In addition, other histone code modulators such as HDA2, SET10, and SIR2A/B are likely involved in epigenetic var gene regulation. d Mutations
in kelch13 (K13) were found to be the major contributors to artemisinin (ART) resistance identified in drug-resistant parasites in the laboratory as well as
in field isolates. kelch13 mutations appear to arise in a complex array of background mutations (that is, mutations in genes encoding ferredoxin (FD),
apicomplast ribosomal protein S10 (ARPS10), multidrug resistance protein 2 (MDR2), and chloroquine resistance transporter (CRT)), not yet detected in
African parasites. In addition, elevated phosphatidylinositol-3-kinase (PI3K) levels have been observed in ART-resistant parasites and PI3K signaling has
been implicated to impact on the unfolded protein response observed in ART-resistant parasites. H2A.Z/H2B.Z, orange/yellow-paired quarter circles;
H3K4me2/3, light green circles; H3K9ac, dark green circles; H3K9me3, red circles; H3K36me3, blue circles; canonical nucleosomes, grey globes; ApiAP2-G
binding motif; light blue line; ncRNAs, wobbly red lines; mRNAs, wobbly black lines. AP2n other TFs belonging to the ApiAP2 DNA binding protein family,
ncRNA non-coding RNA, TFs transcription factors
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of developmental progress throughout most Plasmodium
lifecycle stages and their disruption abolishes or greatly
reduces parasite development [45, 46]. They bind in a
sequence-specific fashion to motifs generally distributed
upstream of open reading frames (ORFs) and individual
AP2s may have widespread influence; PfAP2-O has been
shown to bind upstream of >500 genes (roughly 10 % of
the parasite ORFs), potentially influencing a wide range
of cellular activities [48].
Through forward genetic screens and comparative
genomics, ApiAP2-G was discovered to function as a
conserved master regulator of sexual commitment in Pf
and Pb. ApiAP2-G binds to a conserved 6/8-mer nucleo-
tide motif enriched upstream of gametocyte-specific
genes and ap2-g itself, leading to an autoregulatory feed-
back loop [49, 50] (Fig. 3b). ApiAP2-G2, another
ApiAP2 family member, acts downstream of ApiAP2-G
during sexual development, functioning as a transcrip-
tional repressor blocking expression of genes required
for asexual development and influencing gametocyte sex
ratios [50, 51]. During the asexual IDC, ap2-g displays
characteristics of epigenetically silenced heterochroma-
tin, such as H3K9me3 marks, binding to HP1 and
localization to the nuclear periphery (reviewed in [52])
(Fig. 3b). However, the previously mentioned knock-
downs of both PfHDA2 and HP1 resulted in increased
gametocyte conversion, likely as a direct consequence of
the loss of H3K9me3 marks and H3K9 hyperacetylation
leading to ap2-g transcriptional activation [27, 29]. This
opens the possibility of a bet-hedging mechanism for
sexual commitment in Plasmodium, regulating sto-
chastic, low-level activation of ap2-g sensitive to en-
vironmental stimuli, as has been shown for several
blood-stage-expressed genes [52, 53]. PTMs such as
lysine acetylation are not restricted to histones and a
recent study has demonstrated that the “acetylome”
impacts >1000 proteins and intriguingly is highly
enriched in the ApiAP2 transcription factor family
[54, 55], although the functional consequences of
these PTMs have yet to be established.
Following their synthesis, eukaryotic mRNAs are proc-
essed and are finally translated by the ribosomal machin-
ery. Translation has long been a focus of malaria
research, not only because it represents a promising tar-
get for antimalarial drugs but also for its potential regu-
latory features [56]. The lack of correlation between
transcript and protein level observed throughout the
Plasmodium lifecycle has fueled researchers’ interest in
post-transcriptional and translational control for decades
[57]. Many features of post-transcriptional/translational
control in malaria parasites are similar to the mecha-
nisms found in other eukaryotes [41]. However, the
advent of ribosome profiling [58] has enabled in-depthgenome-wide analysis of the Plasmodium translatome.
Throughout the IDC, transcription and translation are
tightly coupled and only 8 % (approximately 300 tran-
scripts) of the transcriptome was found to be transla-
tionally regulated [59]. These genes were found to be
involved in merozoite egress and invasion, and while
transcript level peaked during the late stages of the IDC,
maximal translation was observed during the early ring
stage. This observation resembles a general feature of
gene expression in Plasmodium, whereby for a set of
genes transcription and translation are uncoupled and
mRNA translation occurs during a later developmental
time point when compared with maximal transcriptional
activity, most notably in female gametocytes [46, 60–64].
This is especially true for genes required for develop-
mental progression and provides the parasite with the
capability of rapid and timely protein synthesis without
the need for preceding de novo mRNA synthesis.
Recently, PfALBA1, a member of the DNA/RNA-
binding Alba protein family, was postulated to act as
master regulator during the Pf IDC, controlling trans-
lation of invasion-related transcripts (Fig. 3a) as well
as regulating mRNA homeostasis of approximately
100 transcripts in blood-stage parasites [65]. In
contrast to findings by Caro and colleagues [59], an
earlier study using polysome profiling found a dis-
crepancy between steady-state mRNA level and
polysome-associated mRNAs among 30 % of genes
(1280 transcripts) during the Pf IDC, indicative of
translationally controlled gene expression [66]. Add-
itionally, the results of this study, as well the findings
of others, suggest upstream ORF translation and stop
codon read-through in Pf [67–69], but the genome-
wide extent of such mechanisms in Plasmodium spp.
remains controversial [59]. Hence, expansion of these
studies to other parasite life stages, such as the
gametocyte, where translational control is firmly
established, would surely give further insights into the
extent of translation regulation in Plasmodium.
In addition to canonical protein-coding mRNAs, a vast
number of genes encoding different ncRNAs have been
identified within the Plasmodium genome in recent
years, which are believed to exert a variety of regulatory
functions (reviewed in [70]). Circular RNAs (circRNAs)
are among the newest members of the still expanding
catalogue of existing ncRNAs in Plasmodium [17]. Host
microRNAs (miRNAs) have been shown to regulate
parasite translation [71], and circRNAs therefore might
act as sponge for host miRNAs, a mechanism described
in other organisms [72]. Recent studies have especially
increased our knowledge of the role of ncRNAs in var
gene regulation (discussed in the next section) but,
nevertheless, the biological role of the vast majority of
these ncRNA species remains unclear.
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In their attempts to occupy a diverse range of host envi-
ronments, protozoan parasites of the Plasmodium genus
have evolved a plethora of molecular mechanisms to
evade the host adaptive immune response. The host
immune response to Plasmodium infection is dependent
upon both host and parasite genomics and the develop-
mental stage and phenotype of the invading parasite
[73–75]. In the best-studied example in Plasmodium,
virulence of Pf is attributed largely to monoallelic
expression of just one of approximately 60 var genes
that encode variant copies of the surface antigen, Pf
erythrocyte membrane protein 1 (PfEMP1). The ability
to switch expression from one var gene to another enables
the invading parasite to alternate between phenotypes
of variable cytoadherent and immunogenic properties
[76–78]. PfEMP1 proteins are expressed at parasite-
induced knobs on the infected erythrocyte surface,
which are electron-dense features comprising many
parasite proteins anchored to the erythrocyte cytoskel-
eton. Failure to present PfEMP1 in such knob structures
greatly reduces the ability of the infected erythrocyte to
bind to its specific host receptor [79].
Pf var gene regulation is complex and includes
mechanisms of gene regulation such as chromosomal
organization and subnuclear compartmentalization
[80, 81], endogenous var gene clustering and var pro-
moter–intron pairing [82, 83], transcriptional gene silen-
cing via exoribonuclease-mediated RNA degradation [84],
histone variant exchange at var promoters [85, 86], the ef-
fect of trans antisense long non-coding RNAs (lncRNAs)
[87], and the presence or absence of histone modifications
and their associated histone-modifying enzymes [27, 29,
40, 87–92] (Fig. 3c). Interest in delineating these mecha-
nisms has continued, and even grown, as more research in
the post-genomic area has highlighted the important dif-
ferential role of the 5′ upstream promoter families into
which the var genes can be subdivided into five classes
(upsA to upsE), which correlate closely with the severity of
malaria infection in the human host [93–98]. Pf var gene
promoters are also essential components of the gene silen-
cing mechanism and monoallelic expression. The upsC
var promoter in particular is necessary to maintain
chromosome-internal var genes in their silenced state and
recently has been proposed to do so through the inter-
action of cis-acting MEE2-like sequence motifs and
MEE2-interacting factors to reinforce var gene transcrip-
tional repression [75, 83].
Monoallelic var gene transcription is also associated
with the presence of H3K9me3 repressive marks at silent
var gene loci (Fig. 3c). This histone modification is
predicted but not proven to be imposed by the HKMT
PfSET3 and is associated with perinuclear repressive
centers and the binding of PfHP1, stimulatingheterochromatin formation [40, 89, 90, 92]. Conditional
disruption of one of these essential proteins, HP1, dis-
rupts singular var gene expression and dysregulates anti-
genic variation [29]. In addition, conditional knockdown
of PfHDA2 has been shown to result in a dramatic loss
of monoallelic var gene expression [27]. This implicated
PfHDA2 as an upstream regulator of HP1 binding as it
facilitates the establishment of the H3K9me3 mark. The
indispensable role of the dynamic histone lysine methy-
lation of Plasmodium chromatin by histone lysine
demethylases (HKDMs) and HKMTs in controlling the
transcription of nearly all var genes has also been
demonstrated. Knockout of the Pf hkmt gene encoding
SET2/SETvs (vs, variant-silencing) resulted in reduced
presence of the repressive H3K36me3 mark at the TSSs
and intronic promoters of all var gene subtypes (Fig. 3c).
Loss of this SETvs-dependent histone modification re-
sulted in the loss of monoallelic var gene expression and
expression of the entire var repertoire [98]. Furthermore,
SETvs can directly interact with the C-terminal domain
of RNA polymerase II, with SETvs disruption resulting
in a loss of binding to RNA polymerase II and var gene
switching [99].
Pf upsA-type var gene expression is also regulated by
PfRNaseII, a chromatin-associated exoribonuclease. An
inverse relationship exists between transcript levels of
PfRNaseII and upsA-type var genes, with an increase in
the latter corresponding to incidences of severe malaria
in infected patients [84]. PfRNaseII is proposed to
control upsA-type var gene transcription by marking
TSSs and intronic promoter regions, degrading potential
full-length transcripts to produce short-lived cryptic
RNA molecules that are then further degraded by the
exosome immediately upon expression (Fig. 3c). Disrup-
tion of the pfrnaseII gene resulted in loss of this degrad-
ation and the generation of full-length upsA var gene
transcripts and intron-derived antisense lncRNA. These
data illustrate the relationship between PfRNaseII and
the control of monoallelic var gene transcription and
suggest a correlation between lncRNA and var gene
activation in Pf [84]. The role of lncRNAs in Pf var gene
activation was again investigated in a study by Amit-
Avraham and colleagues [87], which demonstrated dose-
dependent transcriptional activation of var genes by
overexpression of their individual antisense lncRNA
transcripts. Disruption of antisense lncRNA expression
by peptic nucleic acids resulted in downregulation of
active var gene transcripts and induced var gene switch-
ing. The exact mechanism by which antisense lncRNAs
act to promote the active transcription of a var gene is
unknown. It has been postulated that antisense var
transcripts may recruit chromatin-modifying enzymes that
in turn would affect gene accessibility for the Pf transcrip-
tional machinery. Antisense var gene lncRNAs would also
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insulator-like pairing elements that bind specific nuclear-
binding proteins, therefore blocking the silencing activity
of pairing elements by hybridization [87, 100].
The Plasmodium helical interspersed subtelomeric pro-
tein (PHIST) family of genes, which is unique to Pf, has
also been implicated in the regulation of immune evasion
as a result of its ability to bind to the intracellular acidic
terminal segment of PfEMP1. Conditional knockdown of
the essential PHIST protein PfE1605w reduced the cap-
ability of the infected host erythrocyte to adhere to
the CD36 endothelial receptor, an important virulence
feature of Pf. This study highlighted the importance
not only of var genes and their controlled expression
but also of other genes that are associated with an-
choring PfEMP1 to the erythrocyte surface and creat-
ing the Plasmodium cytoadherence complex [101].
The list of regulatory mechanisms underlying var gene
monoallelic expression is vast and much more may still
be discovered in this area. However, immune evasion in
the Plasmodium genus is not confined to Pf or var gene
regulation. Indeed, var gene expression is exclusive to Pf,
with much still to be gleaned in the areas of immune
evasion in human malaria parasites such as P. vivax, P.
knowlesi, Plasmodium ovale and Plasmodium malariae
[13, 102–105]. In addition, PfEMP1 is just one of a
number of variant surface antigens (VSAs) known to be
expressed at the host erythrocyte surface upon infection
with Pf, although it is the best characterized. Pf-infected
erythrocytes also express VSAs of the multi-copy gene
families of the proteins repetitive interspersed family
(RIFIN), subtelomeric variable open reading frame
(STEVOR), and Pf Maurer’s cleft 2 transmembrane
(PfMC-2TM) [106]. The roles of these protein families in
antigenic variation and pathology are generally poorly de-
fined but are being elucidated; for example, RIFINs are
implicated in the severity of Pf malaria in African children
with blood group A. This tendency toward increased mal-
aria pathogenicity is a result of their expression at the sur-
face of infected host erythrocytes, from which they bind
uninfected erythrocytes (preferentially, blood group A) to
form rosette structures and mediate binding to the host
microvasculature [107]. Thus, the combined roles of HP1
and HDA2 in regulating single var gene expression and
the transcriptional regulator ApiAP2-G suggests that both
processes share epigenetic regulatory mechanisms and
that Plasmodium immune evasion and transmission to
new hosts are inextricably linked [27, 29].
Immune evasion is not restricted to blood-stage Plas-
modium; when the parasite passes through the mosquito
it must also combat a sophisticated innate immune sys-
tem that is very effective in reducing the parasite burden
experienced by the vector. A forward genetic screen and
WGS was used to identify the key parasite factor, thesurface protein PfS47 (found on the surface of the ooki-
nete as it penetrates the mosquito midgut), that appears
to interact with and suppress the vector innate immune
system [108]. PfS47 is thought to suppress signaling
through the c-Jun N-terminal kinase (JNK) pathway that
is critical to an effective immune response [109]. WGS
demonstrated that PfS47 has a distinct population struc-
ture linked to global distribution. PfS47 is rapidly evolv-
ing and selected to achieve JNK suppression in diverse
mosquito species, which becomes a key step in the adap-
tation of Pf to transmission in different vectors, thereby
contributing to its broad global distribution [110].
Artemisinin resistance
The goals of MalariaGEN characterize a new approach
to understanding parasite population biology. Through
the generation and, these days more critically, the man-
agement and analysis of the colossal datasets that result
from WGS of large numbers of samples, a well-
organized study can draw meaningful conclusions. This
was applied to perhaps the most serious threat to mal-
aria control that has emerged in recent years—resistance
to ART. Using these datasets in meta-analyses with clin-
ical data describing the individual WGS-sequenced sam-
ples and outcomes of ART treatment allowed a path to
be charted that associated SNPs with treatment features
(such as delayed clearance) [111] and identified candi-
date genes [112]: in both studies a region of chromo-
some 13 was implicated (Fig. 3d). The precise gene
encoding the protein KELCH13 was identified by a com-
bination of “old-fashioned” selection of drug-resistant
parasites in the laboratory followed by WGS and com-
parative genomics of the sensitive parental parasites and
the progeny, as well as WGS of ART-resistant field iso-
lates [113, 114]. The role of the kelch13 mutations in
ART resistance was proven by direct genome engineer-
ing of kelch13 to generate resistant parasites [115, 116].
kelch13 SNPs have been used to map the alarmingly
rapid spread of resistance throughout Southeast Asia
[116] and it is clear that there is already significant but
distinct kelch13 heterogeneity in African Pf strains,
although there is no evidence of ART resistance
[117–121]. However, in-depth analysis of Southeast
Asian ART-resistant parasite genomes [122] revealed that
a complex array of background mutations (Fig. 3d) in a
variety of genes (encoding ferredoxin (FD), apicoplast
ribosomal protein S10 (ARPS10), multidrug resistance
protein 2 (MDR2), and Pf chloroquine resistance trans-
porter (CRT)) that are not yet described in African
parasites would explain why ART resistance is not (yet) a
threat to the use of ART in that continent [121].
A further puzzle was the large number of independent
SNPs that seemed capable of mediating ART resistance—
typically drug resistance is generated by one or a small
Kirchner et al. Genome Medicine  (2016) 8:92 Page 11 of 17number of SNPs focused on either altering the target
binding site for the drug or preventing drug access to a
binding site buried in the target structure. KELCH pro-
teins are propeller proteins with an iterated structural
motif that serves as a platform for the assembly of multi-
protein complexes. In addition, KELCH13 has a BTB/
POZ domain that might be involved in homodimerization,
E3 ubiquitin ligase binding, and transcriptional repression
(reviewed in [123]). It has been suggested that ART-
resistance-associated kelch13 SNPs might cause a degree
of reduced binding of Pf phosphatidylinositol-3-kinase
(PI3K), which in turn results in its reduced ubiquitination
and consequent degradation of PI3K (Fig. 3d). Elevated
levels of PI3K generate increased amounts of its lipid
product phosphatidylinositol-3-phosphate (PI3P), which
then changes the physiological state of the parasite cell
through signaling in as yet unknown pathways [124] but
through a mechanism predicated on the proposed abun-
dance of PI3P in the lumen of the endoplasmic reticulum
and its proposed role in protein export beyond the para-
site vacuole within the host cell [125]. However, aspects of
this view have been challenged [126] and further studies
are clearly required to resolve the possible role of PI3K
signaling in ART resistance. It will be of interest to see if
PI3K signaling impacts upon the unfolded protein re-
sponse implicated in ART resistance using population
transcriptomics [127]. The WGS data and two proteomics
studies [128, 129] that demonstrate the wide variety of
proteins from different cellular compartments of the tar-
get parasite that interact with activated ART together sug-
gest that ART resistance is a pleiotropic phenomenon
[123]. Therefore, other interrogations, such as metabolo-
mics (see next section), might also be needed to gain func-
tional insights into ART’s mode of action.
Translational implications for malaria control
Antimalarials
WGS has been instrumental in identifying the cellular
target of novel Pf antimalarials as part of the drug dis-
covery pipeline and in following the in vitro selection of
resistant parasite lines and validation of observed gen-
omic changes by reverse genetics as described for ART
above. This approach has proved highly successful for
spiralindolines [130], resulting in the identification of
the target of NITD609 (also known as KAE609 or cipar-
gamin) as the P-type ATPase PfATPase4. Furthermore,
the translation elongation factor eEF2 has been identi-
fied as the target of the 2,6-disubstituted quinoline-4-
carboxamide scaffold derivative DDD107498 [131]. WGS
is not the only post-genome approach that is useful for
determining modes of drug action; metabolomics has a
similar potential for analyzing the metabolic changes
produced in response to drug exposure and has been
utilized in antibiotic [132] and anti-protozoan drug [133]investigations. A metabolomics-based approach also has
the advantages that parasite lines resistant to the drug
need not be generated and that the activity of pleiotropi-
cally acting drugs (such as ART) are directly observed
rather than imputed from genomes of resistant parasites.
Vaccines
Post-genomic approaches have also identified promising
new Pf vaccine candidates. For example, Pf reticulocyte-
binding protein homologue 5 (RH5) binds to the human
red cell surface receptor protein basigin, an interaction
that is essential for erythrocyte invasion by Pf [134]. Re-
cent WGS studies have shown that both the host and
parasite proteins are highly conserved, that antibodies to
RH5 block merozoite invasion of erythrocytes [135, 136],
and that basigin itself is druggable by recombinant anti-
bodies [137]. Although RH5–basigin interaction offers
great promise, the challenges for vaccine development
remain considerable and many promising candidates
have fallen or will fall by the wayside due to an inability
to formulate them to deliver effective vaccination,
massive candidate gene sequence variability, and func-
tional non-essentiality of the candidate. WGS will help
identify non- or minimally variant candidates and should
prove useful in monitoring the effect of vaccination and
the analysis of “breakthrough” parasites (those developing
in vaccinated individuals), as described in the next section.
Effective subunit vaccines will be an invaluable additional
approach to vaccination, supplementing other approaches
such as the use of the promising but technologically chal-
lenging attenuated whole parasite, for example, sporozoite
vaccine [138].
Surveillance
The identification of genome signatures of resistance
through WGS in the laboratory and increasingly through
large-scale genomic epidemiology provides a powerful tool
to monitor the emergence of resistance in Plasmodium
populations under selective pressure due to administration
of both drugs and vaccines. In the case of drugs whose
targets have been identified in the laboratory, specific,
simple PCR-based assays can be devised. WGS of field
parasites under drug pressure is still desirable, however, as
alternative resistance mechanisms might emerge that
would be missed by targeted assays and, with sufficient
depth of sampling, new signatures of resistance would be
identifiable from the sequence data. Similar surveillance of
parasites that emerge post-vaccination might also be in-
formative. An important analysis of the clinical trial of the
RTS,S/AS01 malaria vaccine compared the strain-specific
sequence of the gene encoding the circumsporozoite (CS)
protein that comprised the vaccine with the CS gene se-
quences of strains in the infections actually encountered
by immunized individuals (between 5 and 17 months of
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tection was greater than protection against heterologous
strains and that a cause of failure to protect was simply
that the CS protein carried by the infecting parasites did
not match that of the vaccine and so perhaps a protective
effect was less likely [139]. Therefore, WGS has the power
to guide vaccine design based upon the outcomes of trials.
Gene editing
A new era of genetic engineering has dawned with the
discovery and development of the bacterial guide RNA
template-targeted clustered regularly interspaced short
palindromic repeats (CRISPR)-Cas9 recombinases as
tools for the accurate editing of genomes. The technol-
ogy has been successfully adapted to many species, in-
cluding Plasmodium [140], Anopheles [141, 142], and
humans (discussed in [143]). Currently, applications of
CRISPR-Cas9 to Plasmodium manipulation are re-
stricted to reverse genetic investigations of gene func-
tion. However, with the concepts of whole (pre-
erythrocytic) parasite vaccines [144, 145], CRISPR-Cas9
offers an obvious route towards the generation of an
immunogenic, non-pathogenic parasite that might be
suitably safe to administer to humans as a vaccination
strategy. Clearly, the engineering of human genomes at
any stage of gestation is fraught with ethical consider-
ations [146] and it is inconceivable that this will be ap-
plied to the improvement of human resistance to
malaria in the foreseeable future. Conversely, although
subject to similar ethical and ecological debate, signifi-
cant conceptual advances towards the generation of
CRISPR-Cas9-engineered Anopheles mosquitoes have
been quickly achieved. Through harnessing the concept
of gene drive, two independent teams have reported the
generation of either engineered Anopheles stephensi (a
major Indian vector of malaria) that is resistant to mal-
aria [141] or sterile female Ag [142]. Again, owing to
ecological considerations, it is unlikely that such engi-
neered mosquitoes, although clearly feasible, will be re-
leased into the wild any time soon [147].
Conclusions and future directions
Despite the progress summarized here, the fundamental
requirements of malaria research in any era remain the
same; namely, new drugs to replace those that become in-
effective, vaccines that work, and the means to administer
them effectively. Genomics, post-genomic technologies,
and associated computing developments have revolution-
ized investigations into the biology of the malaria parasite
and the search for therapeutics or intervention measures.
Significant progress has been made on many fronts, in-
cluding candidate drug and vaccine discovery, parasite
drug resistance mechanisms, host–parasite–vector inter-
actions and parasite biology, and mechanisms of humanresistance to malaria. Also, new concepts of combatting
malaria via engineered mosquito populations have been
introduced through the advent of novel genome-editing
approaches such as CRISPR-Cas9.
We can anticipate that WGS will continue to improve
in terms of both cost and quality, making sequencing of
every desirable Pf isolate feasible. This would enable
more detailed studies of population structure and dy-
namics, allowing the tracking of gene flow and genotype
success that might even resolve at the village level and,
further, potentially almost in real time. However, this will
only happen if data storage, access, and computing tech-
nologies keep pace. Where Pf WGS studies have gone P.
vivax research will follow and recent studies have re-
vealed signatures of drug selection superimposed upon a
far more complex (global, regional, and even within a
single infection) population structure than Pf [148, 149].
Single-cell RNA sequencing will significantly improve
our understanding of antigenic variation and variant and
sex-specific gene expression.
More immediately, an important need is for surveil-
lance, particularly in Africa, to look for kelch13 muta-
tions and genotypes associated with ART resistance and
a pan-African network is in place to monitor for this
and collect samples [150]. Genomics will continue to be
used in novel ways as well, for example, in studies of the
outcomes of human interventions such as drug treat-
ment and vaccination.
New fields of endeavor are also emerging that will cer-
tainly prove fruitful in the years to come. Lipidomics is a
nascent discipline that will no doubt reveal insights into
membrane composition and organization [151] and
might also open avenues to therapy. PTMs such as pal-
mitoylation give proteins the means to conditionally
interact with membranes and Plasmodium makes exten-
sive use of protein palmitoylation that should influence a
range of important parasite biological activities, such as
cytoadherence and drug resistance [152].
Although the power of genomics approaches is quite
clear, direct biological investigations are frequently re-
quired to confirm or refute the findings that genomics
might imply. The numerous examples given here indicate
that although genomic analyses often generate associa-
tions and degrees of confidence about their conclusions,
unequivocal confirmation is provided by genetic engineer-
ing (of parasites and their vectors at least). Genetic screens
are powerful, often unbiased approaches to discover gene
function. The recent development of the PlasmoGEM
resource coupled with high-efficiency transfection and
barcoded vectors permits genome-scale reverse genetics
screens to be deployed that will undoubtedly reveal infor-
mation about parasite-specific genes and Plasmodium
biology [153]. Finally, many of the genes encoded by para-
site, host, and vector genomes have unknown functions,
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and assays improve. The staggering complexity of organis-
mal biology and the interactions between parasite, host,
and vector will continue to amaze but equally will offer
hope for new and improved therapies.
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